Format

Send to

Choose Destination
Med Sci (Paris). 2019 Dec;35(12):1034-1042. doi: 10.1051/medsci/2019227. Epub 2020 Jan 6.

[Antibody-drug conjugates in oncology. Recent success of an ancient concept].

[Article in French; Abstract available in French from the publisher]

Author information

1
Institut de Recherche Pierre Fabre, Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint-Julien-en-Genevois, France.
2
Cancer Research Center of Lyon (CRCL), Inserm 1052/CNRS, 69000 Lyon, France - Université de Lyon, 69000 Lyon, France - Hospices Civils de Lyon, 69000 Lyon, France.
3
GICC EA7501, Université de Tours, équipe IMT, 31 avenue Monge, 37200 Tours, France.

Abstract

in English, French

An Antibody-Drug Conjugate (armed antibody) is a vectorized chemotherapy that results from the grafting of a cytotoxic agent on a monoclonal antibody thanks to a judiciously designed spacer arm. ADCs have made considerable progress in 10 years. In 2009, only gemtuzumab ozogamicin (Mylotarg®) was used clinically. In 2019, 4 other ADCs have been approved and more than 80 others are in active clinical trials. The first part of this review will focus on Food and Drug Administration-approved Antibody-Drug Conjugates, their limitations as well as their associated toxicity and resistance mechanisms.

PMID:
31903915
DOI:
10.1051/medsci/2019227

Supplemental Content

Full text links

Icon for EDP Sciences
Loading ...
Support Center